Sanofi: Settlement with Lilly about SoloStar litigation

BUY, Fair Value EUR103 vs. EUR102 (+22%)
News published on September Tuesday 29, 2015
Share on

Sanofi and Lilly have settled their patent dispute in the US. As a consequence, biosimilar Lantus SoloStar will not hit the US market before mid December next year. 2016 is therefore likely to be clean of major headwinds and Sanofi is given 6 extra months to transform its Diabetes franchise.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities